FORTIFIDE: Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trial

FORTIFIDE trial design

Phase 1b/2a, double-blind, placebo-controlled, three-arm, randomized study evaluating a 4-hour infusion of certepetide (LSTA1) when added to standard of care (SoC) in patients with second-line metastatic pancreatic ductal adenocarcinoma (mPDAC) who have progressed on FOLFIRINOX.

Certepetide is an experimental drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. In other words, the study drug is not yet available for use outside of a clinical trial.

FORTIFIDE trial objective

The main goal of the clinical trial is to test the safety and therapeutic effect of certepetide when given as a 4-hour infusion in combination with SoC in subjects with second-line mPDAC who have progressed on FOLFIRINOX. Haystack Oncology MRD™ technology will be used to measure ctDNA for early efficacy exploration.

Locations Actively Recruiting Clinical Trial Patients

The principal investigator is the physician responsible for the scientific and technical direction of the clinical trial at each respective location.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided below. Please refer to this study as LSTA1-P06.

UNITED STATES 

North Carolina, USA

FirstHealth of the Carolinas, Inc.

Pinehurst, North Carolina, United States, 28374

Contact: Lindsey Ferry | tel: 910-715-2200 | email: lferry@firsthealth.org

Principal Investigator: Charles Kuzma, MD

Who may participate in this clinical trial

Joining a clinical trial is an important and personal decision. Only a qualified healthcare professional can determine whether you are eligible to participate in a clinical trial. However, this information may be beneficial in initiating a conversation with your physician. If you believe this clinical trial might be a good fit and are interested in participating, please take the next step and contact a research site to see if you are eligible.

The FORTIFIDE trial may be an option if you meet the following eligibility criteria:

  • Male or female and a minimum of 18 years of age
  • If you are a female who can get pregnant, you must use appropriate contraception. If you are male with a female partner who can get pregnant, you must use appropriate contraception.
  • Patients that have been diagnosed with metastatic pancreatic ductal adenocarcinoma that cannot be surgically removed
  • Patients that have documented disease progression on first-line standard or modified FOLFIRINOX treatment and are eligible for second-line treatment with nab-paclitaxel and gemcitabine

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study. The study doctor will tell you about all the other criteria that you have to meet in order to participate in this study.

What to expect in this clinical trial

  1. SCREENING:

    Potential participants will be evaluated to see if they qualify for the study for up to 28 days.

  2. RANDOMIZATION:

    Eligible participants will be randomly assigned to one of three study treatment groups.

  3. RUN-IN PERIOD:

    At the first study treatment visit, participants will receive only the certepetide or placebo component of the assigned treatment.

  4. TREATMENT:

    Treatment cycles will begin after the run-in period. Participants will visit the clinic 3 times every 28 days for treatment and tests. Participants will also have CT or MRI scans every 8 weeks while on treatment.

Important Note: This is a clinical trial, which means the purpose is to gather data about the safety and effectiveness of a new drug.
Your participation is voluntary, and you can withdraw from the study at any time.

Frequently asked questions